Humans ; Lymphoma, Mantle-Cell ; pathology ; therapy

American Medical Association ; Humans ; Lymphoma, Mantle-Cell ; therapy ; United States

Aged ; Antineoplastic Combined Chemotherapy Protocols ; Humans ; Lymphoma, Mantle-Cell/therapy*

Multiple lymphomatous polyposis (MLP) is a term used to describe malignant lymphoma of the gastrointestinal tract that manifest as polyposis. MLP is believed to represent gastrointestinal involvement by mantle cell lymphoma (MCL), primarily based on its histologic and immunophenotypic similarities with MCL. We have experienced a case of MCL presented as a peculiar feature of multiple lymphomatous polyposis in a 49-year old male patient. He had been diagnosed diffuse large B cell lymphoma of nasopharynx and treated by radiation therapy and CHOP chemotherapy. He newly developed MCL after 10 years in complete remission of diffuse large B cell lymphoma. After newly developed lymphoma was compared with former diagnosed lymphoma, we concluded that they were not same type each other. We reviewed a total of 13 patients including this case, of MLP, which were reported in various Korean literature, and literatures are reviewed.
B-Lymphocytes* ; Drug Therapy ; Gastrointestinal Tract ; Humans ; Lymphoma* ; Lymphoma, B-Cell ; Lymphoma, Mantle-Cell ; Male ; Middle Aged ; Nasopharynx

Multiple lymphomatous polyposis(MLP) is an interesting clinical entity of non-Hodgkin's lymphoma(NHL) and is defined as B-cell lymphoma characterized by the presence of multiple lymphomatous polyps along the gastrointestinal tract. Recently MLP has been considered as a variant form of mantle cell lymphoma(MCL). The median survival of patients with MCL is only 3 years, and none of the available conventional chemotherapy regimens appears curative. Encouraging results have been reported with high dose chemotherapy with autoSCT and alloSCT for its treatment. We introduce 4 cases of MLP diagnosed as MCL by morphologic and immunologic method. The common clinical findings of these cases were splenomegaly (4/4), multiple intraabdominal lymphadenopathy (4/4), and advanced stage (3/4) at presentation. The overall remission duration was relatively short (5-27 months) and three of four cases relapsed after conventional chemotherapy or autologous stem cell transplant. Our report suggests that MCL presented as MLP is a high risk subgroup of NHL and more aggressive approach may be needed for cure.
Drug Therapy ; Gastrointestinal Tract ; Humans ; Lymphatic Diseases ; Lymphoma ; Lymphoma, B-Cell ; Lymphoma, Mantle-Cell* ; Polyps ; Splenomegaly ; Stem Cells

Aged ; Hodgkin Disease ; pathology ; therapy ; Humans ; Lymphoma, Mantle-Cell ; Male ; Stomach Neoplasms ; secondary

Congresses as Topic ; Drug Delivery Systems ; Hematology ; Humans ; Lymphoma, Mantle-Cell ; drug therapy ; United States

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Humans ; Interferons ; Lymphoma, Mantle-Cell ; drug therapy ; Recurrence ; Thalidomide

Mantle cell lymphoma is a subtype of aggressive non-Hodgkin's lymphoma and usually presents in advanced stages. When treated with a regimen such as CHOP, the median survival is about three years. More aggressive front-line therapy with the hyper-CVAD regimen or high-dose therapy with stem cell support has shown encouraging results in several trials. The addition of rituximab to the chemotherapy regimens, or high-dose therapy, increased the response and survival rates in patients with mantle cell lymphoma. We report a case of mantle cell lymphoma that was successfully treated with aggressive front-line treatment strategies. The patient achieved complete remission with initial hyper-CVAD regimen, and was consolidated with autologous stem cell transplantation and subsequent rituximab.
Drug Therapy ; Humans ; Lymphoma, Mantle-Cell* ; Lymphoma, Non-Hodgkin ; Stem Cell Transplantation* ; Stem Cells* ; Survival Rate ; Rituximab

Humans ; Cardiovascular Diseases/drug therapy* ; Consensus ; Lymphoma, B-Cell ; Lymphoma, Mantle-Cell ; Tyrosine Protein Kinase Inhibitors/therapeutic use*